Lamisil and Transient acantholytic dermatosis - a phase IV clinical study of FDA data

Summary:

Transient acantholytic dermatosis is reported as a side effect among people who take Lamisil (terbinafine hydrochloride), especially for people who are male, 50-59 old, also take Claritin, and have Urticaria.

The phase IV clinical study analyzes which people have Transient acantholytic dermatosis when taking Lamisil. It is created by eHealthMe based on reports of 13,455 people who have side effects when taking Lamisil from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Transient acantholytic dermatosis?

Transient acantholytic dermatosis (a skin condition that causes the appearance of small, red spots on chest and back) is found to be associated with 39 drugs and 124 conditions by eHealthMe. Check the latest studies of Transient acantholytic dermatosis.

On Jul, 13, 2026

13,455 people reported to have side effects when taking Lamisil.
Among them, 22 people (0.16%) have Transient acantholytic dermatosis.

Could Lamisil cause Transient acantholytic dermatosis?

Among these 22 people:

What is the gender of people who have Transient acantholytic dermatosis when taking Lamisil? *

female: 0.0 %
male: 100 %

What is the age of people who have Transient acantholytic dermatosis when taking Lamisil? *

What are other drugs people take besides Lamisil? *

Claritin: 21 people, 95.45%
Zolpidem Tartrate: 15 people, 68.18%
Methotrexate: 15 people, 68.18%
Fluocinonide: 15 people, 68.18%
Lorazepam: 15 people, 68.18%
Prednisone: 15 people, 68.18%
Celebrex: 14 people, 63.64%
Mometasone Furoate: 10 people, 45.45%
Propranolol Hydrochloride: 10 people, 45.45%
Xolair: 10 people, 45.45%

What are other side effects people have besides Transient acantholytic dermatosis? *

Urticaria (rash of round, red welts on the skin that itch intensely): 22 people, 100.00%
Skin Plaque (red, scaly patches to appear on the skin): 22 people, 100.00%
Skin Exfoliation (removal of the oldest dead skin cells): 22 people, 100.00%
Skin Discoloration: 22 people, 100.00%
Rashes (redness): 22 people, 100.00%
Papule: 22 people, 100.00%
Itching: 22 people, 100.00%
Intertrigo (inflammation (rash) of the body folds (adjacent areas of skin)): 22 people, 100.00%
Haemorrhage (bleeding): 22 people, 100.00%
Discomfort: 22 people, 100.00%

What are the existing conditions these people have? *

Urticaria (rash of round, red welts on the skin that itch intensely): 22 people, 100.00%
Joint Injury: 7 people, 31.82%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Transient acantholytic dermatosis?

- Check whether Transient acantholytic dermatosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamisil:

Lamisil (14,080 reports)

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transient acantholytic dermatosis:

Transient acantholytic dermatosis (39 drugs)

Browse all the conditions that are associated with Transient acantholytic dermatosis:

Transient acantholytic dermatosis (124 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.